Hottod - what you have to remember if PYC is attending / presenting at international conferences each year usually around double digit appearances they are also in discussion with a multitude of international pharmaceutical & biotechnology company's each year both big & small regarding deals, collaborations and the like - these don't always result in outcomes (or ones were both parties end up with what they want) but nonetheless they are approached - they've also spoken of low ball offers in the past that they have slapped back. This means that there are always others out there with bitter tastes left in their mouth & one could also assume that attempts to discredit or slow the science aren't out of reach.
If you really want to look at timeframes for BioExec he entered HC as the company launched it's Next Generation Library's with the upgrade resulting in 50x growth. Jannssen extended the scope to target new classes of peptide-drug conjugates and PYC as a whole started to really hit the pedal steering the company to intracellular targets in the "undruggable" space. The company also highlighted "informal approaches" hence putting Griffins Securities up as an advisor - BioExec stopped posting 2 weeks from there.
What I do find interesting is no appearance on Genentech / Roche entering the antimicrobial licensing deal last year but yesterday on the cancer update --- comes out like a machine on a mission. That says to me the news was very good & it's ruffling feathers.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)